Stem cell centre closes doors
Düsseldorf/Cologne – XCell-Center GmbH has been under heavy public pressure since the death of an 18-month-old toddler last year that was apparently caused by one of their treatments. The child was given an injection of autologous bone marrow stem cells into his brain. Other patients have also displayed severe side effects after the disputed stem cell treatment. Since late April, the company has been forced to suspend stem cell therapies, citing alterations in German drug law as the reason for the shut-down. XCell-Center appears not to have licensed its cell therapies. Pursuant to §4b and §144 of the German Medicines Act, a transitional period for advanced therapies that are not routinely produced has run out. At the end of May, the firm announced insolvency and sued its managing director Dr. Cornelis H. Kleinbloesem for having misapplied millions of euros for extravagant parties and luxurious lifestyle.